Company profile: BioXell
1.1 - Company Overview
Company description
- Provider of recombinant protein expression and purification services; stable cell line generation using proprietary ExoIN technology and cGMP-compliant CHO-based platforms; transient protein expression; customized protein expression screening; high-yield recombinant protein production in E. coli, yeast, and mammalian systems; and monoclonal and polyclonal antibody development via hybridoma and phage display.
Products and services
- Stable Cell Line Generation: Engineers stable cell lines via proprietary ExoIN technology on cGMP-compliant CHO-based platforms, enabling durable expression for research programs in autoimmunity and chronic inflammatory disease
- Monoclonal and Polyclonal Antibody Development: Creates custom-engineered monoclonal and polyclonal antibodies via hybridoma and phage display methods for research in autoimmunity and inflammation
- High-Yield Production: Produces multi-system recombinant proteins at elevated yields across E. coli, yeast, and mammalian expression platforms for research applications in immunology and chronic inflammatory disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BioXell
AB2 Bio
HQ: Switzerland
Website
- Description: Provider of drug discovery and development of best-in-class therapies for inflammatory diseases, including Tadekinig alfa, a recombinant IL-18 binding protein restoring the IL-18/IL-18BP balance; a proprietary assay to detect and measure free IL-18; and clinical programs in primary HLH (Phase III), secondary HLH/MAS, and adult-onset Still's disease (Phase II).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AB2 Bio company profile →
Stromedix
HQ: United States
Website
- Description: Provider of drugs targeting fibrosis, organ failure, and cancer, initially focused on chronic indications, with plans to expand into related settings such as acute organ failure and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stromedix company profile →
Allakos
HQ: United States
Website
- Description: Provider of therapeutic antibodies for allergy, inflammatory and proliferative diseases, including AK006, a humanized IgG1 monoclonal antibody targeting Siglec-6 to inhibit mast cell activation and reduce mast cell numbers via antibody-dependent cellular phagocytosis, and AK007, a humanized Siglec-10 antagonist that blocks ligand interaction to restore macrophage and dendritic cell anti-tumor activity and promote anti-tumor immunity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allakos company profile →
Rigel Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule drugs for autoimmune, cancer and metabolic diseases, offering REZLIDHIA (olutasidenib) for relapsed/refractory AML with IDH1 mutation and TAVALISSE (fostamatinib) for adult chronic ITP; pipeline includes R289 for LR-MDS, milademetan (MDM2) for liposarcoma with Daiichi Sankyo, bemcentinib (AXL) for NSCLC with BerGenBio, and R552 (RIPK1) for rheumatoid arthritis with Eli Lilly.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rigel Pharmaceuticals company profile →
Sucampo Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialized biopharmaceuticals addressing unmet medical needs, with marketed products AMITIZA for chronic constipation and IBS-C in adults and RESCULA in Japan for lowering intraocular pressure in glaucoma or ocular hypertension, and a late-stage pipeline including VTS-270 for Niemann-Pick Disease Type C and CPP-1X/sulindac for Familial Adenomatous Polyposis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sucampo Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BioXell
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BioXell
2.2 - Growth funds investing in similar companies to BioXell
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BioXell
4.2 - Public trading comparable groups for BioXell
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →